Novartis Common Stock Total Equity vs Current Deferred Revenue Analysis
NVS Stock | USD 97.44 1.62 1.64% |
Novartis financial indicator trend analysis is infinitely more than just investigating Novartis AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novartis AG ADR is a good investment. Please check the relationship between Novartis Common Stock Total Equity and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Common Stock Total Equity vs Current Deferred Revenue
Common Stock Total Equity vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novartis AG ADR Common Stock Total Equity account and Current Deferred Revenue. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Novartis' Common Stock Total Equity and Current Deferred Revenue is 0.1. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Novartis AG ADR, assuming nothing else is changed. The correlation between historical values of Novartis' Common Stock Total Equity and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Novartis AG ADR are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Common Stock Total Equity i.e., Novartis' Common Stock Total Equity and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.1 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Novartis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novartis' Selling General Administrative is comparatively stable compared to the past year. Discontinued Operations is likely to gain to about 5.5 B in 2024, whereas Enterprise Value is likely to drop slightly above 107.4 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 37.0B | 36.3B | 34.2B | 32.3B | Total Revenue | 52.9B | 51.8B | 46.7B | 46.2B |
Novartis fundamental ratios Correlations
Click cells to compare fundamentals
Novartis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novartis fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 118.4B | 132.1B | 131.8B | 117.5B | 99.9B | 103.1B | |
Short Long Term Debt Total | 29.3B | 38.0B | 31.1B | 28.0B | 26.3B | 18.6B | |
Other Current Liab | 15.4B | 17.5B | 18.0B | 17.2B | 15.1B | 11.4B | |
Total Current Liabilities | 28.3B | 33.1B | 30.2B | 28.7B | 26.4B | 22.0B | |
Total Stockholder Equity | 55.5B | 56.6B | 67.7B | 59.3B | 46.7B | 57.2B | |
Property Plant And Equipment Net | 13.7B | 13.9B | 13.1B | 12.2B | 10.9B | 13.5B | |
Current Deferred Revenue | 236M | 114M | 56M | 123M | 98M | 135.9M | |
Net Debt | 18.2B | 28.4B | 18.7B | 20.4B | 13.0B | 11.0B | |
Retained Earnings | 59.3B | 57.2B | 71.0B | 63.5B | 49.6B | 57.8B | |
Accounts Payable | 5.4B | 5.4B | 5.6B | 5.1B | 4.9B | 4.2B | |
Cash | 11.1B | 9.7B | 12.4B | 7.5B | 13.4B | 7.7B | |
Non Current Assets Total | 88.9B | 102.4B | 86.1B | 80.5B | 69.5B | 73.2B | |
Non Currrent Assets Other | 738M | 892M | 2.2B | 1.1B | 2.2B | 2.1B | |
Cash And Short Term Investments | 11.4B | 11.6B | 28.3B | 18.9B | 14.0B | 13.1B | |
Net Receivables | 8.6B | 8.5B | 8.3B | 8.3B | 9.4B | 8.8B | |
Common Stock Total Equity | 969M | 944M | 936M | 913M | 821.7M | 776.8M | |
Common Stock Shares Outstanding | 2.3B | 2.3B | 2.3B | 2.2B | 2.1B | 1.9B | |
Short Term Investments | 334M | 1.9B | 15.9B | 11.4B | 569M | 540.6M | |
Liabilities And Stockholders Equity | 118.4B | 132.1B | 131.8B | 117.5B | 99.9B | 103.1B | |
Non Current Liabilities Total | 34.6B | 42.3B | 33.8B | 29.4B | 26.8B | 23.6B | |
Inventory | 6.0B | 7.1B | 6.7B | 7.2B | 5.9B | 6.0B | |
Other Current Assets | 2.7B | 2.5B | 2.4B | 2.5B | 1.2B | 2.2B | |
Other Stockholder Equity | (59.4B) | (57.2B) | (71.0B) | (63.6B) | (49.7B) | (47.2B) | |
Total Liab | 62.8B | 75.4B | 64.0B | 58.0B | 53.2B | 45.6B | |
Property Plant And Equipment Gross | 13.7B | 13.9B | 13.1B | 12.2B | 22.8B | 14.0B | |
Total Current Assets | 29.5B | 29.7B | 45.7B | 36.9B | 30.5B | 29.9B | |
Capital Stock | 936M | 913M | 901M | 890M | 825M | 767.6M | |
Short Term Debt | 7.3B | 10.1B | 6.6B | 6.2B | 6.3B | 6.3B | |
Common Stock | 936M | 913M | 901M | 890M | 825M | 767.6M | |
Accumulated Other Comprehensive Income | 54.6B | 55.7B | 66.8B | 58.5B | 45.9B | 52.6B | |
Intangible Assets | 28.8B | 36.8B | 34.2B | 31.6B | 26.9B | 22.4B | |
Other Liab | 12.5B | 14.4B | 9.2B | 7.6B | 8.7B | 8.5B | |
Other Assets | 14.8B | 14.7B | 12.4B | 4.8B | 5.6B | 10.1B | |
Long Term Debt | 20.4B | 26.3B | 22.9B | 20.2B | 18.4B | 12.8B | |
Good Will | 26.5B | 30.0B | 29.6B | 29.3B | 23.3B | 22.0B | |
Treasury Stock | (69M) | (80M) | (53M) | (48M) | (41M) | (43.1M) | |
Property Plant Equipment | 13.7B | 13.9B | 13.1B | 12.2B | 14.0B | 14.0B | |
Net Tangible Assets | 5.6B | (5.5B) | 9.4B | 2.8B | 2.5B | 2.4B | |
Noncontrolling Interest In Consolidated Entity | 77M | 68M | 167M | 81M | 83M | 93.5M | |
Deferred Long Term Liab | 5.4B | 4.7B | 5.5B | 4.4B | 5.1B | 5.8B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Global Correlations Find global opportunities by holding instruments from different markets |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.215 | Dividend Share 3.919 | Earnings Share 4.4 | Revenue Per Share 23.168 | Quarterly Revenue Growth 0.097 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.